KYMR (Kymera Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

KYMR (Kymera Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

KYMRKymera Therapeutics, Inc.

Mkt Cap$7B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$39M

Net Income (TTM)-$311M

EPS (TTM)-$3.69

Free Cash Flow (TTM)-$234M

Gross Margin100.0%

Op. Margin-891.3%

Net Margin-794.4%

FCF Margin-597.8%

P/S Ratio (TTM)180.2x

P/E Ratio (TTM)—

YoY Rev Growth-16.7%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$9M	$9M	-$45M
Q2 23	$17M	$17M	-$43M
Q3 23	$5M	$5M	-$58M
Q4 23	$48M	$48M	-$19M
Q1 24	$10M	$10M	-$58M
Q2 24	$26M	$26M	-$51M
Q3 24	$4M	$4M	-$72M
Q4 24	$7M	$7M	-$81M
Q1 25	$22M	$22M	-$74M
Q2 25	$11M	$9M	-$85M
Q3 25	$3M	-$71M	-$93M
Q4 25	$3M	$79M	-$98M

Valuation

Quarter	P/S	P/E
Q1 23	151.4x	—
Q2 23	136.7x	—
Q3 23	150.8x	—
Q4 23	89.9x	—
Q1 24	89.0x	—
Q2 24	79.8x	—
Q3 24	80.7x	—
Q4 24	150.1x	—
Q1 25	120.0x	—
Q2 25	158.0x	—
Q3 25	161.5x	—
Q4 25	180.2x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$44M	-$48M
Q2 23	-$35M	-$46M
Q3 23	-$32M	-$40M
Q4 23	$8M	-$4M
Q1 24	-$40M	-$47M
Q2 24	-$43M	-$48M
Q3 24	-$50M	-$50M
Q4 24	-$62M	-$63M
Q1 25	-$79M	-$80M
Q2 25	-$60M	-$61M
Q3 25	-$27M	-$27M
Q4 25	-$67M	-$67M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$4M
Q2 23	$11M
Q3 23	$8M
Q4 23	$12M
Q1 24	$7M
Q2 24	$5M
Q3 24	$189K
Q4 24	$936K
Q1 25	$467K
Q2 25	$695K
Q3 25	$181K
Q4 25	$106K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	-1.6%	+17.7%
Q2 23	+43.4%	+14.5%
Q3 23	-50.5%	+14.3%
Q4 23	+196.7%	+22.7%
Q1 24	+8.7%	+24.3%
Q2 24	+55.3%	+27.8%
Q3 24	-20.9%	+21.9%
Q4 24	-84.6%	+31.2%
Q1 25	+114.8%	+41.7%
Q2 25	-55.3%	+25.4%
Q3 25	-26.1%	+25.6%
Q4 25	-61.3%	+14.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$9M	99.1%
Q2 23	$11M	67.7%
Q3 23	$12M	246.5%
Q4 23	$11M	22.8%
Q1 24	$12M	116.3%
Q2 24	$14M	55.9%
Q3 24	$15M	398.4%
Q4 24	$14M	186.6%
Q1 25	$14M	64.4%
Q2 25	$15M	134.3%
Q3 25	$16M	571.7%
Q4 25	$14M	505.3%

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$42M	$13M
Q2 23	$46M	$14M
Q3 23	$48M	$14M
Q4 23	$53M	$14M
Q1 24	$49M	$14M
Q2 24	$59M	$17M
Q3 24	$60M	$15M
Q4 24	$72M	$16M
Q1 25	$80M	$16M
Q2 25	$78M	$18M
Q3 25	$74M	$17M
Q4 25	$84M	$17M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$50M	$347M	$397M
Q2 23	$52M	$315M	$368M
Q3 23	$81M	$277M	$358M
Q4 23	$110M	$265M	$375M
Q1 24	$94M	$427M	$521M
Q2 24	$68M	$442M	$510M
Q3 24	$111M	$439M	$550M
Q4 24	$120M	$368M	$489M
Q1 25	$90M	$373M	$463M
Q2 25	$336M	$330M	$665M
Q3 25	$113M	$393M	$506M
Q4 25	$357M	$491M	$848M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	58M	+0.5%
Q2 23	58M	+0.2%
Q3 23	58M	+0.2%
Q4 23	59M	+0.2%
Q1 24	71M	+20.9%
Q2 24	73M	+3.2%
Q3 24	76M	+4.2%
Q4 24	80M	+5.1%
Q1 25	80M	+0.2%
Q2 25	80M	+0.4%
Q3 25	87M	+8.5%
Q4 25	84M	-3.3%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 18	—	—
FY 19	—	—
FY 20	$454K	75
FY 21	$517K	141
FY 22	$280K	167
FY 23	$420K	187
FY 24	$250K	188
FY 25	$165K	238